Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Genomics/Proteomics
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • R&D 100 Awards
  • Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50

Potential Treatment for E.coli Stalls

By Drug Discovery Trends Editor | June 7, 2011

 A potential life-saving treatment for severe E. coli food poisoning outbreaks developed more than a decade ago hasn’t gone forward into clinical trials because of lack of commercial interest.

University of Adelaide researchers produced a “designer” probiotic bacterium that binds and neutralizes the toxin produced by E. coli, which causes life-threatening attack on the kidneys and blood vessels.

The scientists—Adrienne Paton, MD, Renato Morona, associate professor, and James Paton, professor—showed that mice infected with a highly virulent strain of E. coli were protected by the probiotic bacterium.

The research generated ongoing interest from the scientific and medical community, but the commercial sector hasn’t taken up its development for progress into clinical trials in humans. “Severe E. coli food poisoning outbreaks such as that currently occurring in Europe are becoming increasingly common,” says Paton, director, Research Center for Infectious Diseases in the school of molecular and biomedical science.

“They have the potential to cause widespread disease and many patients develop life-threatening complications including kidney failure,” he adds. The probiotic bacterium could be produced cheaply, however, in spite of on-going attention from the scientific and medical community; there has been a lack of interest from the commercial sector in taking this product into clinical trials.

“If this had been done, and the probiotic had been proven to be safe and efficacious in humans, it could have been deployed during the current European outbreak. This would undoubtedly have saved lives, as well as millions of dollars in current and future health care costs.”

The researchers engineered a harmless bacterium to mimic binding receptors for the potentially fatal Shiga toxin on its surface.Paton says after diagnosis of E. coli infection there was a window of opportunity for therapeutic intervention before kidneys started to fail. Antibiotics are not used because they can increase the amount of toxin released in the gut.

The research was published in Nature Medicine.

Release Date: June 7, 2011
Source: University of Adelaide 


Filed Under: Drug Discovery

 

Related Articles Read More >

Tiffany Hurd
CB Therapeutics biz dev lead sees upside for psychedelics in mental health and beyond
Pharmacovigilance
A new era of pharmacovigilance: Worldwide master key for drug safety monitoring
Takeda Pharmaceutical in the Drug Discovery & Development Pharma 50
Takeda’s Takhzyro fares well in pediatric hereditary angioedema study
Novartis in the Pharma 50
Novartis to cut up to 8,000 positions

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Need Drug Discovery news in a minute?

We Deliver!
Drug Discovery & Development Enewsletters get you caught up on all the mission critical news you need. Sign up today.
Enews Signup
Drug Discovery and Development
  • MASSDEVICE
  • DEVICETALKS
  • Medical Design & Outsourcing
  • MEDICAL TUBING + EXTRUSION
  • MEDTECH 100
  • Medical Design Sourcing
  • Subscribe to our Free E-Newsletter
  • Contact Us
  • About Us
  • Advertise With Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2022 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Genomics/Proteomics
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • R&D 100 Awards
  • Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50